New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 4, 2013
07:31 EDTKERX, AMRNKeryx slide attributable to Zerenex market exclusivity worries, The Street says
The 22% decline in Keryx Pharmaceuticals (KERX) seen on Friday was attributable to concerns raised by a report from IPD Analytics about the company's ability to gain FDA "New Chemical Entity" status for Zerenex, according to The Street's Adam Feuerstein. The author notes that Amarin (AMRN) shares are sometimes volatile over a similar concern, namely that a key drug may not be able to secure NCE status, which grants five years of market exclusivity for a unique pharmaceutical compound. Reference Link
News For KERX;AMRN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 31, 2015
07:17 EDTAMRNAmarin announces two presentations on EPA dyslipidemia studies
Amarin announced the presentation of findings from two studies, a retrospective study in which patients were switched from an EPA plus DHA combination product to EPA-only Vascepa as well as a sub-analysis of the ANCHOR clinical trial, at two key cardiovascular meetings. The EPA+DHA to EPA-only switch study investigated the effect of EPA-only omega-3 therapy compared to EPA+DHA therapy on multiple patient lipid parameters. Results of this case series showed a reduction in both triglyceride and low-density lipoprotein cholesterol levels with EPA-only therapy in most of these high-risk statin-treated patients. The ANCHOR sub-analysis is an encore presentation which examined the effect of EPA on high-risk statin-treated patients with persistently high triglyceride levels, showing that icosapent ethyl increased EPA in plasma and red blood cells in a linear, dose-dependent fashion consistent with its triglyceride-lowering effect.
July 29, 2015
10:41 EDTKERXOptions with increasing implied volatility
Subscribe for More Information
10:27 EDTKERXOptions with decreasing implied volatility
Subscribe for More Information
July 27, 2015
08:26 EDTKERXKeryx appoints Scott Holmes as CFO
Keryx Biopharmaceuticals announced the appointment of Scott A. Holmes to CFO effective immediately. Holmes will be responsible for Keryx's finance function and will be a member of the company's executive team. He will succeed James Oliviero whose planned departure was announced earlier this year. Oliviero will stay with the company through a transition period. Holmes brings nearly 20 years of life sciences and financial management expertise to Keryx. He joins the company from AMAG Pharmaceuticals where he most recently served as senior vice president, finance and investor relations during a period of high growth driven by acquisitions and public financings. Prior to AMAG, from 2009 to 2011, he was vice president of finance and treasurer of Molecular Biometrics.
July 24, 2015
16:38 EDTAMRNAmarin files to sell 38.9M series A preference shares in form of ADS for holders
Subscribe for More Information
16:34 EDTAMRNAmarin files to sell 3.89M ordinary shares in form of ADS for holders
Subscribe for More Information
07:13 EDTKERXKeryx receives CHMP positive opinion for Fexeric
Subscribe for More Information
July 23, 2015
10:00 EDTKERXOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:06 EDTKERXKeryx downgraded to Market Perform from Outperform at Cowen
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use